中国医院用药评价与分析2024，Vol.24Issue(4)：417-421,5.DOI:10.14009/j.issn.1672-2124.2024.04.007
卡瑞利珠单抗联合化疗在EGFR/ALK野生型的晚期非鳞状非小细胞肺癌老年患者中的临床观察
Clinical Observation of Camrelizumab Combined with Chemotherapy in the Elderly with EGFR/ALK Wild-Type,Advanced Non-Squamous Non-Small Cell Lung Cancer
摘要
Abstract
OBJECTIVE:To observe the efficacy and safety of camrelizumab combined with chemotherapy in the elderly with epidermal growth factor receptor/anaplastic lymphoma kinase(EGFR/ALK)wild-type,advanced non-squamous non-small cell lung cancer(NSCLC).METHODS:A total of 133 patients with EGFR/ALK wild-type,advanced non-squamous NSCLC who received camrelizumab combined with chemotherapy in the First Affiliated Hospital of Chongqing Medical University from Aug.2021 to Feb.2023 were extract to be divided into the elderly group(≥65 years old)and non-elderly group(<65 years old)according to patients'age.Therapeutic effect and safety of two groups were analyzed retrospectively.RESULTS:The median progression-free survival in the elderly group was greater than that in the non-elderly group(44.14 weeks vs.37.71 weeks).The survival curves of two groups were tested and compared by Log-rank method,with no statistically significant difference(P>0.05).The objective response rate and disease control rate of the elderly group were lower than those of the non-elderly group[objective response rate:5.33%(4/75)vs.6.90%(4/58);disease control rate:74.67%(56/75)vs.75.86%(44/58)],the difference was not statistically significant(P>0.05).The incidence of treatment-related adverse event(TRAE)in all grades of the elderly group was 97.33%(73/75),which was higher than 84.48%(49/58)of the non-elderly group,with statistically significant difference(P<0.05).The incidence of TRAE above grades 3 in the elderly group and non-elderly group was respectively 10.67%(8/75)and 5.17%(3/58),with no statistically significant difference(P>0.05).CONCLUSIONS:Treatment efficacy were the same in the elderly patients as in non-elderly patients with EGFR/ALK wild-type,advanced non-squamous NSCLC in camrelizumab combined with chemotherapy.Elderly patients have a higher incidence of TRAE;initially,no dose adjustment of camrelizumab is required for the elderly receiving treatment.关键词
卡瑞利珠单抗/非小细胞肺癌/老年患者/有效性/安全性Key words
Camrelizumab/Non-small cell lung cancer/Elderly patients/Efficacy/Safety分类
医药卫生引用本文复制引用
唐一丁,谭逢艳,蒙龙,宋捷,邱峰,龙锐..卡瑞利珠单抗联合化疗在EGFR/ALK野生型的晚期非鳞状非小细胞肺癌老年患者中的临床观察[J].中国医院用药评价与分析,2024,24(4):417-421,5.基金项目
重庆市医学科研项目(卫生健康委员会和科技局联合)(No.2023MSXM041) （卫生健康委员会和科技局联合）
